NEU neuren pharmaceuticals limited

Ann: 2023 Results webinar, page-11

  1. 717 Posts.
    lightbulb Created with Sketch. 585
    An excellent measured and I believe accurate assessment of the current situation by JP - I really rate this guy.

    His assessment of the Culper report - "the report has zero credibility, the author has zero credibility". He was disappointed it has had as much airtime as it has in Australia.

    In response to a question about the recent SP weakness for both ACAD and NEU, I think he was spot on in his assessment that the Culper report primed investor emotions to look for any perceived weaknesses (eg persistence) rather than see the overwhelming positive success of Daybue staring them in the face. He spent a bit of time talking about persistence and how it is tracking ahead of expectations and is baked into guidance.

    Importantly, with all the Daybue hullabaloo since the Culper sham, he gave us a gentle reminder of something I have also posted about which is that the main game for NEU is NNZ-2591, not Daybue. He continues to have extremely high conviction in 2591 which gives me great comfort. Also mentioned they are considering further indications for it.

    With all this Culper rubbish that has been going on and the SP gyrations it has caused, it's important to remember this about NEU -

    NNZ-2591 = forest
    Daybue sales = trees


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.23
Change
0.380(2.96%)
Mkt cap ! $1.652B
Open High Low Value Volume
$13.15 $13.37 $12.92 $4.258M 324.6K

Buyers (Bids)

No. Vol. Price($)
5 83 $13.22
 

Sellers (Offers)

Price($) Vol. No.
$13.24 120 2
View Market Depth
Last trade - 12.17pm 18/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.